Characteristics and auxological data at baseline and at near-adult height for patients with idiopathic growth hormone deficiency, organic growth hormone deficiency or Turner syndrome who were growth hormone treated or growth hormone naive at study entry
| Characteristic | Diagnostic category; mean (95% CI)* | ||||
|---|---|---|---|---|---|
| All patients | Organic growth hormone deficiency | Idiopathic growth hormone deficiency | Turner syndrome | Idiopathic short stature | |
| Canada | n = 293 | n = 131 | n = 50 | n = 79 | n = 10 |
| Baseline | |||||
| Male sex, no. (%) | 147 (50.2) | 89 (67.9) | 33 (66.0) | – | 9 (90.0) |
| Age, yr | 10.2 (9.8 to 10.6) | 9.2 (8.5 to 9.9) | 11.4 (10.4 to 12.5) | 10.3 (9.8 to 10.9) | 12.8 (11.3 to 14.4) |
| Height SDS | −2.62 (−2.78 to −2.46) | −2.29 (−2.57 to −2.00) | −2.70 (−3.06 to −2.33) | −2.99 (−3.15 to −2.83) | −2.52 (−3.25 to −1.79) |
| Target height SDS deficit† | −2.51 (−2.69 to −2.32) | −2.32 (−2.62 to −2.02) | −2.14 (−2.56 to −1.71) | −2.91 (−3.11 to −2.71) | −1.81 (−2.61 to −1.01) |
| Height velocity SDS | −1.49 (−1.71 to −1.27) | −1.89 (−2.23 to −1.54) | −1.29 (−1.75 to −0.83) | −1.16 (−1.44 to −0.89) | −0.25 (−1.32 to 0.83) |
| Growth hormone dosage, mg/kg per wk | 0.22 (0.21 to 0.23) | 0.18 (0.17 to 0.18) | 0.20 (0.17 to 0.23) | 0.29 (0.28 to 0.29) | 0.24 (0.18 to 0.30) |
| Stimulated peak growth hormone level, μg/L | 4.73 (3.99 to 5.47) | 2.90 (2.48 to 3.32) | 4.15 (3.36 to 4.94) | NA | 19.41 (14.65 to 24.18) |
| Near-adult height | |||||
| Age, yr | 17.8 (17.6 to 17.9) | 18.1 (17.8 to 18.3) | 17.6 (17.1 to 18.1) | 17.6 (17.3 to 17.9) | 17.2 (15.6 to 18.9) |
| Height SDS | −1.42 (−1.56 to −1.27) | −0.95 (−1.15 to −0.75) | −1.07 (−1.38 to −0.76) | −2.04 (−2.24 to −1.83) | −2.02 (−2.89 to −1.14) |
| Near-adult height SDS less baseline height SDS | 1.17 (1.01 to 1.33) | 1.26 (0.98 to 1.54) | 1.63 (1.27 to 1.99) | 0.96 (0.78 to 1.13) | 0.50 (−0.35 to 1.35) |
| Target height SDS deficit† | −1.28 (−1.44 to −1.13) | −0.93 (−1.15 to −0.71) | −0.52 (−0.80 to −0.24) | −1.94 (−2.16 to −1.72) | −1.31 (−2.29 to −0.32) |
| Growth hormone therapy duration, yr | 6.46 (6.01 to 6.90) | 7.68 (6.93 to 8.44) | 5.45 (4.48 to 6.42) | 5.71 (5.18 to 6.25) | 3.19 (1.97 to 4.42) |
| Last growth hormone dosage, mg/kg per wk | 0.22 (0.21 to 0.23) | 0.17 (0.16 to 0.18) | 0.20 (0.19 to 0.22) | 0.29 (0.28 to 0.30) | 0.24 (0.18 to 0.30) |
| Near-adult height SDS > −2.0, no. (%) | 66 | 79 | 80 | 46 | 50 |
| All countries combined (including Canada) | n = 5076 | n = 754 | n = 2322 | n = 695 | n = 552 |
| Baseline | |||||
| Male sex, no. (%) | 2576 (50.7) | 448 (59.4) | 1412 (60.8) | – | 360 (65.2) |
| Age, yr | 10.9 (10.8 to 11.0) | 9.8 (9.5 to 10.1) | 11.2 (11.1 to 11.3) | 10.0 (9.8 to 10.3) | 12.3 (12.0 to 12.5) |
| Height SDS | −2.42 (−2.45 to −2.40) | −2.27 (−2.38 to −2.17) | −2.38 (−2.41 to −2.34) | −2.65 (−2.71 to −2.58) | −2.37 (−2.43 to −2.30) |
| Target height SDS deficit† | −2.02 (−2.06 to −1.99) | −2.29 (−2.40 to −2.17) | −1.80 (−1.85 to −1.76) | −2.69 (−2.77 to −2.61) | −1.74 (−1.83 to −1.65) |
| Height velocity SDS | −1.01 (−1.07 to −0.95) | −1.51 (−1.69 to −1.33) | −0.98 (−1.06 to −0.89) | −1.04 (−1.22 to −0.87) | −0.63 (−0.80 to −0.47) |
| Growth hormone dosage, mg/kg per wk | 0.27 (0.26 to 0.27) | 0.22 (0.21 to 0.22) | 0.25 (0.24 to 0.25) | 0.32 (0.31 to 0.32) | 0.33 (0.32 to 0.34) |
| Stimulated peak growth hormone level, μg/L | 9.46 (9.18 to 9.74) | 4.18 (3.80 to 4.55) | 8.26 (7.95 to 8.57) | 14.06 (12.50 to 15.61) | 16.49 (15.51 to 17.47) |
| Near-adult height | |||||
| Age, yr | 17.3 (17.2 to 17.3) | 18.0 (17.8 to 18.2) | 17.2 (17.1 to 17.3) | 17.1 (16.9 to 17.3) | 17.2 (17.0 to 17.4) |
| Height SDS | −1.18 (−1.21 to −1.15) | −0.80 (−0.90 to −0.69) | −1.01 (−1.05 to −0.97) | −1.70 (−1.77 to −1.63) | −1.26 (−1.34 to −1.18) |
| Near-adult height SDS less baseline height SDS | 1.24 (1.21 to 1.27) | 1.46 (1.35 to 1.58) | 1.37 (1.33 to 1.41) | 0.95 (0.89 to 1.01) | 1.10 (1.02 to 1.19) |
| Target height SDS deficit† | −0.76 (−0.79 to −0.77) | −0.73 (−0.83 to −0.62) | −0.43 (−0.47 to −0.39) | −1.74 (−1.81 to −1.66) | −0.60 (−0.70 to −0.51) |
| Growth hormone therapy duration, yr | 5.82 (5.72 to 5.91) | 7.59 (7.26 to 7.91) | 5.51 (5.37 to 5.64) | 6.38 (6.12 to 6.63) | 4.67 (4.44 to 4.91) |
| Last growth hormone dosage, mg/kg per wk | 0.28 (0.28 to 0.28) | 0.20 (0.19 to 0.21) | 0.27 (0.26 to 0.27) | 0.32 (0.31 to 0.33) | 0.36 (0.35 to 0.37) |
| Near-adult height SDS > −2.0, no. (%) | 81 | 84 | 86 | 66 | 82 |